Neurotech International Ltd
ASX:NTI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its Industry Average (13.8), the stock would be worth AU$0.06 (396% upside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.8 | AU$0.01 |
0%
|
| Industry Average | 13.8 | AU$0.06 |
+396%
|
| Country Average | 13.2 | AU$0.06 |
+374%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Neurotech International Ltd
ASX:NTI
|
16.9m AUD | 2.8 | -4.4 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 55.3 | 58.7 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 16.8 | 25.6 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 24.9 | 38.7 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 14.6 | 23.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 19.7 | 25.1 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 30.7 | 44.7 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40.1B EUR | 13.2 | 19 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 38.8 | 43.3 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 12.6 | 24.4 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 16.9 | 21.8 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 8.9 |
| Median | 13.2 |
| 70th Percentile | 19.2 |
| Max | 8 864.3 |
Other Multiples
Neurotech International Ltd
Glance View
Neurotech International Ltd. engages in the research, designing, marketing, and through third party manufacturers, production of wearable neurotechnology devices to assist with neurological conditions such as autism. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2016-11-04. The firm operates through its wholly owned, Malta-based subsidiary AAT Research Limited. The firm is focusing on neuro-protective, anti-inflammatory and neuro-modulatory activities of NTI/Dolce cannabis strains. The firm through its class II device Mente is focused on development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism. Mente is, a home therapy that is clinically proven to increase engagement and relaxation in autistic children with elevated Delta band brain activity.
